C A Wijbrandts

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

Rogier M. Thurlings, Koen Vos, C A Wijbrandts et al. · Annals of the Rheumatic Diseases · 2007 · 329 citations · Full text

Medicine, Immunology, Internal Medicine +17

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium

C A Wijbrandts, M.G.W. Dijkgraaf, Maarten C. Kraan et al. · Annals of the Rheumatic Diseases · 2007 · 152 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss

C A Wijbrandts, Rolf Anton Klaasen, M.G.W. Dijkgraaf et al. · Annals of the Rheumatic Diseases · 2008 · 148 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

CTLA‐4IG suppresses reactive oxygen species by preventing synovial adherent cell–induced inactivation of rap1, a ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells

PHJ Remans, C A Wijbrandts, M. Sanders et al. · Arthritis & Rheumatism · 2006 · 46 citations

Life Sciences, Clinical Sciences, Immunology +17

Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6‐month course of TNF inhibitors: prospective intervention study and partial economic evaluation

Jan L. Hoving, G. M. Bartelds, J. K. Sluiter et al. · Scandinavian Journal of Rheumatology · 2009 · 44 citations

Pharmacy, Internal Medicine, Pharmacotherapy +17